Clinical Trial Update: Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 adjuvant study of pyrotinib for HER-2 positive breast cancer is currently recruiting, with RenJi Hospital listed as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: RenJi Hospital | Conditions: Locally Advanced Breast Cancer | Phase 3 | Status: RECRUITING